Our highly successful Lipoprotein (a) test is the only method in the world to accurately and reliably measure Lp(a), it is not affected by Apo (a) size related bias like most other methods.

Elevated Lp(a) concentration in plasma is an independent genetic marker correlating with increased risk of atherosclerotic disorders including myocardial and cerebral infarction. Levels are also elevated in nephritic syndrome, patients undergoing renal dialysis, patients with uncontrolled diabetes mellitus and hypothyroidism.

In June 2010, the European Atherosclerosis Society (EAS) published a consensus paper on Lp(a), recommending its widespread use as a screening tool in those at intermediate or high risk of cardiovascular disease. Click here to view the paper.